Visual Inspection in pharma is a check for visible particles, leaks, and defects before batch release. WHO says all parenteral containers should be inspected individually (100% units), and defect types should be categorized and trended. It requires illumination and controlled inspection rates.
Under Good Manufacturing Practices (GMP), the SOP should define training, method sequence, risk-based defect classification, and documentation. EU GMP Annex 1 expects manual inspectors to be qualified at least annually using samples from the manufacturer’s defect library, with eyesight checks. This article helps QA, QC, production, and validation teams build or review a visual inspection process that stands up in audits.
Table of Contents
What is Visual Inspection in Pharma?
Visual Inspection in pharma means trained staff check each unit for visible defects. Teams look for particles, cracks, leaks, wrong fill level, and cosmetic damage. They protect patients and prevent batch release errors.
Therefore, teams set strict inspection conditions and document decisions in controlled records. QA, QC, production, and validation teams align criteria and trend rejects daily.
Classify defects as critical, major, or minor to guide actions.
Use defined lighting, backgrounds, and rotation time to reduce misses.
Validate methods with challenge sets, then analyze trends and CAPA triggers.
Download the FDA draft guidance: Inspection of Injectable Products for Visible Particulates (December 2021, PDF). As Sample Visual inspection Guidance Here
What Is Checked During Visual Inspection?
Inspectors check every unit for visible particles or haze in the solution. They also check container damage, cracks, leaks, and seals. They verify fill level, clarity, and stopper or cap defects. Example: EU GMP Annex 1 expects 100% inspection of parenteral containers.
Therefore, teams set defect limits and record every reject with a code. FDA’s draft guidance (December 2021) does not recommend more than one reinspection in an attempt to release a batch with atypical defect levels. Inspectors trend rejects by defect type and line speed each shift. Validation teams qualify lighting, background, and rotation time to improve detection.
Common Defects Checked During Visual Inspection (Defect, Example, Risk, Action)
| Defect | Risk | Action |
|---|---|---|
|
Visible particles / fibers |
Critical |
Reject; investigate; CAPA if trending |
|
Cracks / chips |
Critical |
Reject; check handling and equipment |
|
Wrong fill level |
Major |
Reject; adjust filler; document |
|
Haze / cloudy solution |
Major/Critical |
Reject; assess batch trend |
Risk classes are examples only. Define each defect’s criticality during qualification, based on risk, historical knowledge, potential patient impact and route of administration.
Scope of Visual Inspection in Pharmaceutical Products
Scope defines which products, containers, and defects your Visual Inspection covers. Poor scope causes missed particles, false rejects, and weak investigations. Therefore, follow GMP data: WHO expects individual inspection of all parenteral filled containers.
Use this scope to align QA, QC, production, and validation reviews.
Document boundaries in SOP and records.
1) Products Covered by Visual Inspection (Sterile and Non-Sterile)
Sterile products need visual inspection because patients receive them directly. Teams inspect injectables, ophthalmics, and sterile irrigations for particles and container defects. However, non-sterile products also need checks for mix-ups and damage.
QC includes topical creams, syrups, and powders when appearance signals quality issues.
Tablets: chips, discoloration, and wrong imprint.
Liquids: haze, sediment, and label or cap errors.
2) Container Types Included in Inspection Scope
Include vials, ampoules, syringes, cartridges, bottles, blisters, tubes, and IV bags for batch release. FDA’s draft guidance states that each final container of an injectable product must be inspected (100% inspection) using a qualified method, and that units found to contain visible particulates must be rejected.
Therefore, include container parts: stoppers, seals, crimps, caps, and labels. Set defect rules for cracks, chips, leaks, dents, scuffs, loose closures, and label tears.
3) Defects and Attributes Evaluated During Inspection
Inspectors look for defects that can harm patients or block release. They check product appearance, container integrity, and correct presentation. They code each reject and trend results by batch and line.
Therefore, use a clear defect list and consistent definitions across teams.
Visible particles, fibers, or glass flakes in solution.
Cracks, chips, leaks, or weak seals.
Wrong fill level, foam, or haze.
Missing stopper, loose cap, or damaged crimp.
Label mix-ups, wrong text, or poor print quality.
4) In-Process vs Finished Product Visual Inspection Scope
In-process visual inspection checks defects during filling, sealing, and labeling. It helps production stop the line and prevent repeat defects.
Therefore, finished product inspection confirms final units meet release criteria. QA and QC review rejects, trends, and deviations before disposition.
In-process: operators check closure and label setup.
Finished product: inspect for visible contamination and visible container or closure defects. Perform container closure integrity testing separately using an appropriate validated method.
Official Visual Inspection Guidelines and PDFs to Know
Several official documents shape how inspectors judge a visual inspection programme. Use the current version of each one, and note whether it is a GMP requirement, guidance or a compendial chapter.
EU GMP Annex 1 (2022). The revised Annex 1 came into operation on 25 August 2023. Section 8.30 states that all filled containers of parenteral products should be inspected individually, while sections 8.31 to 8.33 cover manual inspection conditions, annual inspector qualification, validation of automated systems and defect trending. Section 8.22 adds that visual inspection is not an acceptable integrity test method. For a wider audit view, see our EU GMP Annex 1 audit checklist.
WHO TRS 1044, Annex 2. WHO’s good manufacturing practices for sterile pharmaceutical products apply the same individual-inspection principle in section 8.30, which makes the document a useful reference for markets that follow WHO GMP.
FDA draft guidance: Inspection of Injectable Products for Visible Particulates (December 2021). It describes a holistic, risk-based approach to visible particulate control, from product development to inspection, investigation and corrective action. However, it is still a draft with non-binding recommendations, and it does not cover subvisible particulates or other physical defects such as container integrity flaws or fill volume.
USP General Chapters <790> and <1790>. Chapter <790> Visible Particulates in Injections and Chapter <1790> Visual Inspection of Injections are the main compendial references for this topic, and FDA’s draft guidance refers to them. The chapters themselves are published in the USP–NF.
Inspection SOP for Pharmaceutical Products (Sterile and Nonsterile)
The SOP standardizes Visual Inspection for sterile and nonsterile products. It defines station controls: black/white background, lighting level, and viewing time. It sets handling: rotate units, avoid bubbles, and prevent contamination.
Therefore, it defines defect codes, reinspection rules, and reject reconciliation for trending. Validation verifies setup, timing, and defect detection. SOP headings:
Scope
Equipment and setup
Inspection method
Defect criteria
Records and escalation
Core SOP Elements for Visual Inspection
Core SOP elements define how teams run Visual Inspection consistently. They reduce misses, false rejects, and inconsistent defect calls across shifts.
Therefore, QA, QC, production, and validation align on these technical sections:
Training, eyesight checks, and annual requalification.
Inspection setup: lighting, background, speed, and handling rules.
Defect library, reject codes, trending, and CAPA triggers.
Training and Qualification Requirements
Under FDA’s draft guidance, only certified inspectors and qualified equipment should inspect injectable products, and personnel who perform 100% and AQL inspections must be adequately trained, with periodic retraining or requalification as appropriate. Inspector candidates should also know the relevant CGMP requirements, have normal near visual acuity (with or without corrective lenses) and show no colour-vision impairment. To qualify them, quality assurance prepares and approves test sets that mix good and defective units, while the quality unit controls these sets and keeps defective units masked. As a typical draft recommendation, defective units should not exceed 10–20 percent of a test set; however, this figure guides test-set design, not batch rejection. In the EU, Annex 1 adds that manual inspectors should qualify at least annually, wearing their usual corrective lenses. Moreover, qualification should use defect-library samples, reflect worst-case scenarios such as inspection time, line speed where a conveyor feeds the operator, container size or fatigue, and consider eyesight checks.
Inspection Method and Sequence
Inspect each parenteral container individually and check for contamination and defects. Run manual inspection under controlled illumination and background, and qualify inspection rates.
Therefore, categorize defects and trend defect counts to spot unusual reject levels. Trigger an investigation if you later find any critical defect in accepted units.
Defect Classification and Reject Handling
Classify defects to support consistent reject decisions and batch disposition. Use critical, major, and minor categories linked to patient risk.
Segregate rejected units, identify their status, and control their handling under the approved procedure so that they cannot be unintentionally returned to accepted product.
Therefore, handle rejects with controlled rules and full traceability.
Record defect code, time, line, and inspector ID.
Reconcile rejects versus produced counts every shift.
Trigger deviation and CAPA when trends exceed alert limits.
Keep Qualification Evidence Traceable to Routine Inspection
A qualification result is useful only when the test conditions can be connected to the work being authorised. Record which product and container presentation the exercise represents, which inspection method was used, and which acceptance criteria applied. Keep the test duration, grading method, results, and any action after a failed test with the approved qualification protocol.
FDA’s draft guidance recommends quality-unit control of test sets to reduce bias. The identity of defective units should be masked from the person being assessed. Include suitable examples of detectable defects, rather than choosing only conspicuous particles that make the exercise easier than routine work. The guidance also describes maintaining examples near the lower limits of visual detection and evaluating newly identified particulate defects for inclusion in the training library.
For an automated method, keep evidence of the representative defects used to challenge the system and the conditions under which they were detected. Annex 1 expects challenges before start-up and at intervals during the batch. A successful qualification record should therefore be understandable alongside the operating conditions it supports, rather than standing alone as a certificate with no technical context.
100% Inspection, AQL Sampling and Reinspection: How They Fit Together
A robust visual inspection programme combines three layers. First comes 100% inspection. FDA’s draft guidance recommends performing it at the stage where visible particulates are most likely to be detected in the final container, for example before labeling, to maximise container clarity.
Second, the quality unit should sample each batch for acceptance quality limit (AQL) testing after 100% inspection. This sample provides an independent check on the inspection itself. Under EU GMP Annex 1, critical defects should not be found in later sampling of accepted containers, and any critical defect found there should trigger an investigation.
Third, reinspection must stay controlled. If a batch shows atypical defect levels, reinspection should follow approved SOPs with tightened acceptance criteria. FDA’s draft guidance does not recommend more than one reinspection in an attempt to release such a batch. Units that fail the AQL reinspection should be counted with all other rejects, so that every unit in the batch is reconciled.
Finally, automated systems follow the same logic. Annex 1 expects them to be validated to detect known defects, to perform at least as well as manual inspection, and to be challenged with representative defects before start-up and at regular intervals throughout the batch.
Interpret Reject Trends Before Making a Batch Decision
A reject total is easier to interpret when the denominator is visible. As an illustrative calculation, two rejected units among 1,000 inspected units represent 0.2%; three among 3,000 represent 0.1%. The second batch has more rejected units but a lower observed proportion. These figures are arithmetic examples, not acceptance limits or evidence of acceptable process performance.
Keep counts separated by defect type and identify the inspected population and relevant process conditions. Annex 1 calls for statistical trending of reject levels and investigation of unusual defect levels against routine and trend data. A shift in defect type can matter even when the overall reject percentage appears unchanged. Avoid treating an overall average as an explanation for a new particulate finding.
When investigating an adverse trend, consider the possible effect on marketed product as well as the batch under review. WHO’s sterile-product GMP text explicitly includes that assessment. Document the investigation, the evidence considered, and the rationale for any follow-up. Passing a later inspection does not, by itself, explain why the original adverse trend occurred.
Final Words
Visual Inspection in pharma checks parenteral units for contamination and defects. EU GMP Annex 1 says all filled parenteral containers must be inspected individually; set defect criticality during qualification and trend defect levels by batch. This helps QA, QC, production, and validation teams align scope and reject rules.
Write an SOP covering illumination/background, sequence, inspector training, defect codes, and trending. EU GMP Annex 1 also expects 100% integrity testing of glass ampoules, BFS units and small-volume containers (≤100 ml) closed by fusion, and states that visual inspection is not an acceptable integrity test method. Use both controls to reduce risk and support audits.
FAQs
No. Teams inspect parenterals (sterile injectables) plus many non-sterile products where appearance signals quality (e.g., discoloration, damaged packs). WHO expects individual inspection of all filled parenteral containers.
Inspectors assess visible particles and other visible product, container, closure, or presentation defects within the defined inspection scope. Visible damage can identify a unit for rejection or investigation, but visual inspection does not demonstrate container closure integrity. EU GMP Annex 1 section 8.22 requires a separate, validated approach for integrity testing.
Define scope, inspection conditions, defect classification/criticality, training/qualification, and batch performance trending.
For injectable products, FDA’s December 2021 draft guidance describes 100% visual inspection using a qualified method and rejection of units containing visible particulates. Its recommendations should not be presented as a general inspection standard for every non-injectable presentation.
Ershad Moradi
Ershad Moradi, a Content Marketing Specialist at Zamann Pharma Support, brings 6 years of experience in the pharmaceutical industry. Specializing in pharmaceutical and medical technologies, Ershad is currently focused on expanding his knowledge in marketing and improving communication in the field. Outside of work, Ershad enjoys reading and attending industry related networks to stay up-to-date on the latest advancements. With a passion for continuous learning and growth, Ershad is always looking for new opportunities to enhance his skills and contribute to pharmaceutical industry. Connect with Ershad on Facebook for more information.
Ethical Pharmaceutical Marketing: Must-Know Rules for Trusted Growth
Discover the must-know principles of ethical pharmaceutical marketing, from balanced clinical claims and HCP transparency to digital compliance, performance KPIs, and trust-driven growth.
Drug Commercialization Process: Avoid Costly Mistakes and Launch with Confidence
Master the drug commercialization process, from regulatory approvals and GMP launch readiness to market access, pricing, compliant marketing, and post-launch KPIs. Discover strategies to minimize risks and achieve a successful pharmaceutical launch.
Medical Device CRO: Hidden Secrets of Successful Clinical Trials
Discover how a medical device CRO supports safer clinical trials, ensures ISO 14155, FDA IDE, and EU MDR compliance, strengthens monitoring and data quality, and helps you choose the right clinical research partner.